Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies

Leukemia and Lymphoma

Volumn 47, Issue 6, 2006, Pages 978-985

  Friedrichs, Birte ^a   Siegel, Sandra ^a   Hald Andersen, Mads ^b   Schmitz, Norbert ^a   Zeis, Matthias ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Hematological malignancies; Immunotherapy; Survivin; Tumor antigens; Vaccination

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; INHIBITOR OF APOPTOSIS PROTEIN; SURVIVIN; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; APLASTIC ANEMIA; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELL DIVISION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MALIGNANT NEOPLASTIC DISEASE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FAMILY; PROTEIN FUNCTION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PEPTIDES; T-LYMPHOCYTES;

EID: 33746290181     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500464062     Document Type: Review

References (75)

1. Rosenberg, S. (2001) Progress in human tumour immunology and immunotherapy Nature, 411, pp. 380-384.
2. Boon, T and van Baren, N. (2003) Immunosurveillance against cancer and immunotherapy - synergy or antagonism? N Engl J Med, 348, pp. 252-254.
3. Gilboa, E. (1999) The makings of a tumor rejection antigen Immunity, 11, pp. 263-270.
4. Coulie, P and Bruggen, P. (2003) T-cell responses of vaccinated cancer patients Curr Opin Immunol, 15, pp. 131-137.
5. Kolb, H and Schmid, C and Barrett, A and Schendel, D. (2004) Graft-versus-leukemia reactions in allogeneic chimeras Blood, 103, pp. 767-776.
6. Caligiuri, M and Velardi, A and Scheinberg, D and Borrello, I. (2004) Immunotherapeutic approaches for hematologic malignancies Hematology, pp. 337-353.
7. Ambrosini, G and Adida, C and Altieri, D. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nat Med, 3, pp. 917-921.
8. Tamm, I and Wang, Y and Sausville, E and Scudiero, D and Vigna, N and Oltersdorf, T and et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs Cancer Res, 58, pp. 5315-5320.
9. Shi, Y. (2004) Caspase activation, inhibition, and reactivation: A mechanistic view Protein Sci, 13, pp. 1979-1987.
10. Chiou, S and Jones, M and Tarnawski, A. (2003) Survivin - an anti-apoptosis protein: Its biological roles and implications for cancer and beyond Med Sci Monit, 9, pp. I25-I29.
11. Li, F and Altieri, D. (1999) The cancer antiapoptosis mouse survivin gene: Characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression Cancer Res, 59, pp. 3143-3151.
12. Wang, C and Mayo, M and Korneluk, R and Goeddel, D and Baldwin, A, Jr. (1998) NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation Science, 281, pp. 1680-1683.
13. Altieri, D. (2003) Validating survivin as a cancer therapeutic target Nat Rev Cancer, 3, pp. 46-54.
14. Ambrosini, G and Adida, C and Sirugo, G and Altieri, D. (1998) Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting J Biol Chem, 273, pp. 11177-11182.
15. Skoufias, D and Mollinari, C and Lacroix, F and Margolis, R. (2000) Human survivin is a kinetochore-associated passenger protein J Cell Biol, 151, pp. 1575-1582.
16. Giodini, A and Kallio, M and Wall, N and Gorbsky, G and Tognin, S and Marchisio, P and et al. (2002) Regulation of microtubule stability and mitotic progression by survivin Cancer Res, 62, pp. 2462-2467.
17. Mahotka, C and Wenzel, M and Springer, E and Gabbert, H and Gerharz, C. (1999) Survivin-deltaEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties Cancer Res, 59, pp. 6097-6102.
18. Caldas, H and Honsey, L and Altura, R. (2005) Survivin 2alpha: A novel Survivin splice variant expressed in human malignancies Mol Cancer, 4, pp. 11.
19. Thompson, C. (1995) Apoptosis in the pathogenesis and treatment of disease Science, 267, pp. 1456-1462.
20. O'Connor, D and Schechner, J and Adida, C and Mesri, M and Rothermel, A and Li, F and et al. (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells Am J Pathol, 156, pp. 393-398.
21. Du, C and Fang, M and Li, Y and Li, L and Wang, X. (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition Cell, 102, pp. 33-42.
22. Verhagen, A and Ekert, P and Pakusch, M and Silke, J and Connolly, L and Reid, G and et al. (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins Cell, 102, pp. 43-53.
23. LaCasse, E and Baird, S and Korneluk, R and MacKenzie, A. (1998) The inhibitors of apoptosis (IAPs) and their emerging role in cancer Oncogene, 17, pp. 3247-3259.
24. Olie, R and Simoes-Wust, A and Baumann, B and Leech, S and Fabbro, D and Stahel, R and et al. (2000) A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy Cancer Res, 60, pp. 2805-2809.
25. Otto, K and Andersen, M and Eggert, A and Keikavoussi, P and Pedersen, L and Rath, J and et al. (2005) Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin Vaccine, 23, pp. 884-889.
26. Gianani, R and Jarboe, E and Orlicky, D and Frost, M and Bobak, J and Lehner, R and et al. (2001) Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa Hum Pathol, 32, pp. 119-125.
27. Fukuda, S and Pelus, L. (2001) Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: Implication of survivin expression in normal hematopoiesis Blood, 98, pp. 2091-2100.
28. Zhang, C and Hazarika, P and Ni, X and Weidner, D and Duvic, M. (2002) Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action Clin Cancer Res, 8, pp. 1234-1240.
29. Carter, B and Milella, M and Altieri, D and Andreeff, M. (2001) Cytokine-regulated expression of survivin in myeloid leukemia Blood, 97, pp. 2784-2790.
30. Kornacker, M and Verneris, M and Kornacker, B and Scheffold, C and Negrin, R. (2001) Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells Immunol Lett, 76, pp. 169-173.
31. Schmidt, S and Schag, K and Muller, M and Weck, M and Appel, S and Kanz, L and et al. (2003) Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells Blood, 102, pp. 571-576.
32. Adida, C and Haioun, C and Gaulard, P and Lepage, E and Morel, P and Briere, J and et al. (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas Blood, 96, pp. 1921-1925.
33. Kawasaki, H and Altieri, D and Lu, C and Toyoda, M and Tenjo, T and Tanigawa, N. (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer Cancer Res, 58, pp. 5071-5074.
34. Lu, C and Altieri, D and Tanigawa, N. (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas Cancer Res, 58, pp. 1808-1812.
35. Swana, H and Grossman, D and Anthony, J and Weiss, R and Altieri, D. (1999) Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer N Engl J Med, 341, pp. 452-453.
36. Monzo, M and Rosell, R and Felip, E and Astudillo, J and Sanchez, J and Maestre, J and et al. (1999) A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers J Clin Oncol, 17, pp. 2100-2104.
37. Tanaka, K and Iwamoto, S and Gon, G and Nohara, T and Iwamoto, M and Tanigawa, N. (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas Clin Cancer Res, 6, pp. 127-134.
38. Satoh, K and Kaneko, K and Hirota, M and Masamune, A and Satoh, A and Shimosegawa, T. (2001) Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors Cancer, 92, pp. 271-278.
39. Velculescu, V and Madden, S and Zhang, L and Lash, A and Yu, J and Rago, C and et al. (1999) Analysis of human transcriptomes Nat Genet, 23, pp. 387-388.
40. Badran, A and Yoshida, A and Yujiwano and Imamura, S and Kawai, Y and Tsutani, H and et al. (2003) Expression of the antiapoptotic gene survivin in chronic myeloid leukemia Anticancer Res, 23, pp. 589-592.
41. Badran, A and Yoshida, A and Wano, Y and Mutoh, M and Imamura, S and Yamashita, T and et al. (2003) Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome Int J Oncol, 22, pp. 59-64.
42. Moriai, R and Asanuma, K and Kobayashi, D and Yajima, T and Yagihashi, A and Yamada, M and et al. (2001) Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells Anticancer Res, 21, pp. 595-600.
43. Shinozawa, I and Inokuchi, K and Wakabayashi, I and Dan, K. (2000) Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies Leuk Res, 24, pp. 965-970.
44. Mori, A and Wada, H and Nishimura, Y and Okamoto, T and Takemoto, Y and Kakishita, E. (2002) Expression of the antiapoptosis gene survivin in human leukemia Int J Hematol, 75, pp. 161-165.
45. Invernizzi, R and Travaglino, E and Lunghi, M and Klersy, C and Bernasconi, P and Cazzola, M and et al. (2004) Survivin expression in acute leukemias and myelodysplastic syndromes Leuk Lymphoma, 45, pp. 2229-2237.
46. Hernandez-Boluda, J and Bellosillo, B and Vela, M and Colomer, D and Alvarez-Larran, A and Cervantes, F. (2005) Survivin expression in the progression of chronic myeloid leukemia: A sequential study in 16 patients Leuk Lymphoma, 46, pp. 717-722.
47. Granziero, L and Ghia, P and Circosta, P and Gottardi, D and Strola, G and Geuna, M and et al. (2001) Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia Blood, 97, pp. 2777-2783.
48. Sugawara, M and Matsuzuka, F and Fukata, S and Kuma, K and Moatamed, F and Haugen, B. (2002) Excessive survivin expression in thyroid lymphomas Hum Pathol, 33, pp. 524-527.
49. Parker, J and Mufti, G and Rasool, F and Mijovic, A and Devereux, S and Pagliuca, A. (2000) The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS Blood, 96, pp. 3932-3938.
50. Tamm, I and Richter, S and Oltersdorf, D and Creutzig, U and Harbott, J and Scholz, F and et al. (2004) High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia Clin Cancer Res, 10, pp. 3737-3744.
51. Zhu, N and Gu, L and Findley, H and Li, F and Zhou, M. (2004) An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy Oncogene, 23, pp. 7545-7551.
52. Nakayama, K and Kamihira, S. (2002) Survivin an important determinant for prognosis in adult T-cell leukemia: A novel biomarker in practical hemato-oncology Leuk Lymphoma, 43, pp. 2249-2255.
53. Schmitz, M and Diestelkoetter, P and Weigle, B and Schmachtenberg, F and Stevanovic, S and Ockert, D and et al. (2000) Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides Cancer Res, 60, pp. 4845-4849.
54. Andersen, M and Pedersen, L and Capeller, B and Brocker, E and Becker, J and Thor, S. (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients Cancer Res, 61, pp. 5964-5968.
55. Zeis, M and Siegel, S and Wagner, A and Schmitz, M and Marget, M and Kuhl-Burmeister, R and et al. (2003) Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells J Immunol, 170, pp. 5391-5397.
56. Siegel, S and Steinmann, J and Schmitz, N and Stuhlmann, R and Dreger, P and Zeis, M. (2004) Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes Leukemia, 18, pp. 2046-2047.
57. Casati, C and Dalerba, P and Rivoltini, L and Gallino, G and Deho, P and Rini, F and et al. (2003) The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients Cancer Res, 63, pp. 4507-4515.
58. Rohayem, J and Diestelkoetter, P and Weigle, B and Oehmichen, A and Schmitz, M and Mehlhorn, J and et al. (2000) Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients Cancer Res, 60, pp. 1815-1817.
59. Yagihashi, A and Asanuma, K and Nakamura, M and Araya, J and Mano, Y and Torigoe, T and et al. (2001) Detection of anti-survivin antibody in gastrointestinal cancer patients Clin Chem, 47, pp. 1729-1731.
60. Zeis, M and Friedrichs, B and Stuhlmann, R and Siegel, S and Bornhäuser, M and Schmitz, M and et al. (2005) Humoral immune response against the inhibitor of apoptosis protein survivin in patients with hematopoetic malignancies Haematologica, 90(Suppl 2). abstract 0016
61. Andersen, M and Pedersen, L and Becker, J and Straten, P. (2001) Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients Cancer Res, 61, pp. 869-872.
62. Reker, S and Meier, A and Holten-Andersen, L and Svane, I and Becker, J and Thor, S and et al. (2004) Identification of novel survivin-derived CTL epitopes Cancer Biol Ther, 3, pp. 173-179.
63. Pisarev, V and Yu, B and Salup, R and Sherman, S and Altieri, D and Gabrilovich, D. (2003) Full-length dominant-negative survivin for cancer immunotherapy Clin Cancer Res, 9, pp. 6523-6533.
64. Reker, S and Becker, J and Svane, I and Ralfkiaer, E and Straten, P and Andersen, M. (2004) HLA-B35-restricted immune responses against survivin in cancer patients Int J Cancer, 108, pp. 937-941.
65. Hirohashi, Y and Torigoe, T and Maeda, A and Nabeta, Y and Kamiguchi, K and Sato, T and et al. (2002) An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin Clin Cancer Res, 8, pp. 1731-1739.
66. Bachinsky, M and Guillen, D and Patel, S and Singleton, J and Chen, C and Soltis, D and et al. (2005) Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles Cancer Immun, 5, pp. 6.
67. Rammensee, H and Bachmann, J and Emmerich, N and Bachor, O and Stevanovic, S. (1999) SYFPEITHI: Database for MHC ligands and peptide motifs Immunogenetics, 50, pp. 213-219.
68. HLA Peptide Binding Predictions. Bioinformatics and Molecular Analysis Section, NIH. http://www.bimas.dcrt.nih.gov/molbio/hla-bind
69. Andersen, M and Becker, J and Straten, P. (2005) Regulators of apoptosis: Suitable targets for immune therapy of cancer Nat Rev Drug Disc, 5, pp. 399-409.
70. Restifo, N. (2001) Hierarchy, tolerance, and dominance in the antitumor T-cell response J Immunother, 24, pp. 193-194.
71. Gaiger, A and Reese, V and Disis, M and Cheever, M. (2000) Immunity to WT1 in the animal model and in patients with acute myeloid leukemia Blood, 96, pp. 1480-1489.
72. Overwijk, W and Tsung, A and Irvine, K and Parkhurst, M and Goletz, T and Tsung, K and et al. (1998) gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand J Exp Med, 188, pp. 277-286.
73. Vertuani, S and Sette, A and Sidney, J and Southwood, S and Fikes, J and Keogh, E and et al. (2004) Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues J Immunol, 172, pp. 3501-3508.
74. Tsuruma, T and Hata, F and Torigoe, T and Furuhata, T and Idenoue, S and Kurotaki, T and et al. (2004) Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer J Transl Med, 2, pp. 19.
75. Rees, R and Mian, S. (1999) Selective MHC expression in tumours modulates adaptive and innate antitumour responses Cancer Immunol Immunother, 48, pp. 374-381.